Company / Operating Cash Flow
Vistagen Therapeutics, Inc. Operating Cash Flow History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$45.3M
FY2023
5-year range
-$45.3M / -$4.8M
FY2019-FY2023
Trend
-274.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -275% YoY in FY2023, a notable deviation from the 7-year average annual change of -111%.
Based on SEC 10-K filings.
-$45M in FY2023.
Declined from -$16M to -$45M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, operating cash flow decreased 274.8% year-over-year.
- Peak operating cash flow was recorded in FY2011.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$45.3M | -274.8% |
| FY2022 | -$12.1M | +23.4% |
| FY2021 | -$15.8M | -117.0% |
| FY2018 | -$7.3M | -51.0% |
| FY2017 | -$4.8M | -38.8% |
| FY2014 | -$3.5M | +2.9% |
| FY2012 | -$3.6M | -323.8% |
| FY2011 | -$841.3K | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026